Zimmer Biomet Holdings, Inc. $ZBH Stock Position Raised by Minneapolis Portfolio Management Group LLC

Minneapolis Portfolio Management Group LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 300,988 shares of the medical equipment provider’s stock after purchasing an additional 8,189 shares during the quarter. Zimmer Biomet accounts for 2.4% of Minneapolis Portfolio Management Group LLC’s portfolio, making the stock its 25th largest position. Minneapolis Portfolio Management Group LLC owned about 0.16% of Zimmer Biomet worth $26,737,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp bought a new stake in shares of Zimmer Biomet in the second quarter worth $922,000. Hsbc Holdings PLC bought a new position in Zimmer Biomet in the second quarter valued at about $35,417,000. Nykredit A S purchased a new position in Zimmer Biomet in the second quarter worth about $3,419,000. Legal & General Group Plc purchased a new position in Zimmer Biomet in the second quarter worth about $126,167,000. Finally, Rakuten Investment Management Inc. purchased a new position in Zimmer Biomet in the second quarter worth about $2,945,000. Institutional investors own 88.89% of the company’s stock.

Insider Activity

In related news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Chad F. Phipps sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Down 0.0%

Shares of Zimmer Biomet stock opened at $103.18 on Monday. The company has a market capitalization of $19.53 billion, a P/E ratio of 26.12, a P/E/G ratio of 2.42 and a beta of 0.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.79 and a current ratio of 1.46. The company has a fifty day moving average of $95.76 and a 200 day moving average of $92.57. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $112.54.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. Zimmer Biomet’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.56 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.30%.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent research reports. Sanford C. Bernstein increased their price objective on shares of Zimmer Biomet from $93.00 to $107.00 and gave the stock a “market perform” rating in a research note on Thursday, November 5th. Barclays boosted their target price on shares of Zimmer Biomet from $100.00 to $115.00 and gave the company an “equal weight” rating in a research report on Monday, November 9th. Truist Financial set a $114.00 target price on shares of Zimmer Biomet in a report on Thursday, November 5th. Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $103.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 5th. Finally, Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Seven research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $112.74.

Get Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.